AstraZeneca PLC - 2006 Results, Pipeline And Strategy Update Interviews

February 1, 2007 |

1 min read

Results and outlook; Key growth products; Pipeline and portfolio development; Partnerships, collaborations and acquisitions; Re-focusing R&D and the pipeline; Phase III pipeline; Phase II and early stage; Biologics

Earnings Europe

AstraZeneca

MORE ON THIS TOPIC

Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant

Layoff Tracker

GSK restructure will hit home, impacting ‘limited’ UK roles

October 28, 2026

·

110 min read

·

BioSpace Editorial Staff

Balance vaccination and anti-vaccination. Vaccination or Anti-vaccination concept, vector illustration

Earnings

GSK vaccine sales miss expectations amid falling demand from adults

October 28, 2026

·

2 min read

·

Nick Paul Taylor

Hand shake icon on wooden cube block which connection with human icon for business deal and agreement concept.

Immuno-oncology

Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset

October 28, 2026

·

2 min read

·

Tristan Manalac

Business growth or increase in professional income, business operations, investment profits or interest on savings, increase in interest rates, businessman holding gold coins forming a growing arrow symbol.

Earnings

Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis

October 28, 2026

·

1 min read

·

Annalee Armstrong